2023 - rct - Pivotal Reference
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM et al.. N Engl J Med.
Bibliography For Retatrutide
Every Curated Peer-Reviewed Reference Indexed For This Compound. Each Citation Can Be Exported In BibTeX, RIS, EndNote, Or Plain Text.
Indexed Types:labelmonographrctstudy
n.d. - study
Inotropic effects of retatrutide in isolated human atrial preparations.
Unknown Authors.
n.d. - study
Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
Unknown Authors.
n.d. - study
Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis.
Unknown Authors.
n.d. - study
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists.
Unknown Authors.
n.d. - study
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
Unknown Authors.
n.d. - study
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.
Unknown Authors.
n.d. - study
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Unknown Authors.
n.d. - study
Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum.
Unknown Authors.
n.d. - study
Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.
Unknown Authors.
n.d. - study
Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader–Willi syndrome
Unknown Authors.
n.d. - study
Triple Agonism Based Therapies for Obesity.
Unknown Authors.
n.d. - study
Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
Unknown Authors.
n.d. - study
Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives.
Unknown Authors.
n.d. - study
Future Directions in the Medical Treatment of Obesity: A Narrative Review.
Unknown Authors.
n.d. - study
Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.
Unknown Authors.
n.d. - study
The Effects of SGLT2 Inhibitors on Muscle Health in Older Adults: A Systematic Review and Meta-Analysis.
Unknown Authors.
n.d. - study
Beyond weight loss: Preserving muscle health in the incretin era.
Unknown Authors.
n.d. - study
Risk factor obesity: treatment standard.
Unknown Authors.
n.d. - study
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception.
Unknown Authors.
n.d. - study
Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.
Unknown Authors.
n.d. - study
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Unknown Authors.
n.d. - monograph
RxNorm 2722410 (Retatrutide)
Unknown Authors.
n.d. - study
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.
Unknown Authors.
n.d. - study
Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies.
Unknown Authors.
n.d. - study
Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight.
Unknown Authors.
n.d. - study
Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.
Unknown Authors.
n.d. - study
Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.
Unknown Authors.
n.d. - study
Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.
Unknown Authors.
n.d. - study
Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.
Unknown Authors.
n.d. - study
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart.
Unknown Authors.
n.d. - study
Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
Unknown Authors.
n.d. - study
Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Unknown Authors.
n.d. - label
RETATRUTIDE PEN INJECTION, SOLUTION [GUANGZHOU YIXIN CROSS-BORDER E-COMMERCE CO., LTD.]
Unknown Authors.
n.d. - study
Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair.
Unknown Authors.
n.d. - study
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy.
Unknown Authors.
n.d. - study
GIPR:GCGR co-agonism restores normal weight in obese rodents.
Unknown Authors.
n.d. - study
GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research.
Unknown Authors.
n.d. - study
Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials.
Unknown Authors.
n.d. - study
Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression.
Unknown Authors.
n.d. - study
From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling.
Unknown Authors.
n.d. - study
Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.
Unknown Authors.
n.d. - study
Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity.
Unknown Authors.
n.d. - study
Targeting Inflammation in Obesity and the Cardiovascular-Kidney-Metabolic Syndrome Spectrum: A Narrative Review.
Unknown Authors.
n.d. - study
Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.
Unknown Authors.
n.d. - study
Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.
Unknown Authors.
n.d. - study
Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State-of-the-Art Review.
Unknown Authors.
n.d. - study
Effects of Incretin-Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat-Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis.
Unknown Authors.
n.d. - study
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Unknown Authors.
n.d. - study
The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review.
Unknown Authors.
n.d. - study
The use of GLP-1 receptor agonists and co-agonists in adults without diabetes: a systematic review and network meta-analysis protocol.
Unknown Authors.
n.d. - study
Comment on Huttasch et al. Increased Early Postprandial Glucagon Concentrations in Humans With Newly Diagnosed Type 2 Diabetes and Steatotic Liver Disease.
Unknown Authors.
n.d. - study
Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review.
Unknown Authors.
n.d. - study
The Evolution of Medications for Obesity Management.
Unknown Authors.
n.d. - study
From Guidelines to Clinical Practice: Expert Perspectives on Long-Term Management of Obesity.
Unknown Authors.
n.d. - study
Reappraising obesity management in the GLP-1 receptor agonist era.
Unknown Authors.
n.d. - study
Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework.
Unknown Authors.
n.d. - study
Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
Unknown Authors.
n.d. - study
The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?
Unknown Authors.